Surveillance of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2018 from different European territories

• Published in: Journal of global antimicrobial resistance. 2021-09, Vol.26, p.326-329
• Main Authors: Hawser, Stephen, Kothari, Nimmi, Jemmely, Noëlle, Redder, Nowel
• Format: Article
• Language: English
• Subjects: Ceftobiprole; Europe; Susceptibility
• ISSN: 2213-7165; 2213-7173
• DOI: 10.1016/j.jgar.2021.07.012

•Key Gram-positive and Gram-negative pathogens exhibited high susceptibility to ceftobiprole.•Resistance to ceftobiprole in MRSA, MSSA and Streptococcus pneumoniae was particularly low.•Resistance to ceftobiprole in MRSA, MSSA and S. pneumoniae was similar to previous years of ceftobiprole surveillance.•Susceptibility to ceftobiprole was similar in the majority of European countries. Ceftobiprole is approved for the treatment of hospital-acquired and community-acquired pneumonia in 17 different European countries and is currently undergoing clinical trials in the USA. In this study, isolates were collected from hospital laboratories from 15 European countries during 2018 as part of an ongoing post-marketing surveillance study. Minimum inhibitory concentrations (MICs) were determined using European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methodology and were interpreted using 2019 EUCAST breakpoints. Ceftobiprole was active (MIC, ≤2 mg/L) against 100% and 98.9% of methicillin-susceptible Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) from 2018, respectively. Only six MRSA isolates (1.1%) were resistant to ceftobiprole and originated from four countries. Against Streptococcus pneumoniae, ceftobiprole was active (MIC, ≤0.5 mg/L) against 98.7% of isolates. Overall, 75.6% of Enterobacterales were susceptible, although isolate numbers in certain countries were notably low. In addition, based on non-species-related pharmacokinetic/pharmacodynamic breakpoints, 63.2% of Pseudomonas aeruginosa isolates were susceptible to ceftobiprole. Data for ceftobiprole for isolates from 2018 are very similar to studies performed on isolates from earlier years, showing that susceptibility to ceftobiprole has remained high.